Business Wire

CA-CONVIVA

4.11.2021 17:02:13 CET | Business Wire | Press release

Share
Global Streaming Market Still Growing; Up 21% Worldwide According to New Conviva Data

Despite predictions of a ”pandemic peak,” streaming adoption continues to gain ground in almost every single region quarter after quarter, according to the Q3 2021 State of Streaming report from Conviva, the continuous measurement platform for streaming media. Streaming viewing time grew 21% worldwide in Q3 2021 as compared to the same quarter in 2020, led by Africa, Oceania and South America while North America, an established streaming market, held steady with the most modest growth of any region, up just 2%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005139/en/

“Streaming viewing has grown 266% over the past three years, completely transforming the entertainment, publishing and advertising industries,” said Keith Zubchevich, CEO, Conviva. “Topics like quality of experience, advertising measurement and social engagement are now top of mind and the publishers that effectively leverage opportunities to improve in these areas will not only lead the industry in subscribers and viewer satisfaction, but also revenue.”

The report also found streaming publishers investing heavily in video content on social media platforms in Q3 2021 – especially YouTube – in order to test new content and promote their catalog with viewers. In fact, streaming platforms increased their content output on YouTube by 97%, which resulted in an 8.4% increase in views and a 24% increase in engagement. Audiences for streaming platform accounts grew by 66% on YouTube in Q3 2021 as compared to Q3 2020.

Buffering Nearly Eliminated; Higher Quality = Higher Engagement

Q3 2021 marks the first quarter all regions experienced sub-1% buffering, with buffering seeing the largest improvements in more nascent regions like Africa, down 78% year over year. North America had the most modest gains over last year, with a 29% reduction in buffering, which was enough to maintain its position as the region with the least buffering at just 0.19%. Year over year, picture quality also made gains with bitrate improving in every region.

Higher quality delivered higher consumer engagement across the board. When buffering rates were less than 0.4%, viewers engaged for an average of 28.44 minutes in Q3, with that steadily declining with each incremental increase in buffering. Similarly, higher picture quality correlated with higher engagement as viewers averaged more than 20 minutes at bitrates above 3.5 Mbps in Q3 with engagement declining as bitrates dropped.

Big screen domination persisted

Despite seeing a slight decrease in share over Q3 of last year, big screens – which includes connected TV devices, smart TVs and gaming consoles – still accounted for almost three quarters (73%) of viewing time worldwide. Roku, Amazon Fire TV and Samsung TV made up the bulk of big screen viewing time globally with Roku again coming out on top with 31.1% share. Amazon Fire TV fell from 20% in Q3 2020 to 16.8% in Q3 2021, while Samsung gained nearly 3 percentage points over Q3 of last year going from 9.4% to 12.2% share of global viewing time. LG TV, Android TV, Apple TV and Chromecast also gained share over last year.

In every part of the world except Asia, big screens were the majority of viewership, particularly in North America with 82%. Mobile phones, desktops and tablets barely registered in North America at 8%, 6% and 4%, respectively.

Advertising continues advances in streaming

Streaming advertising made significant gains in Q3 2021. Ad attempts and ad impressions were up over 30% in Q3 2021, as compared to Q2 2021. Just 15% of ads in Q3 2021 were not delivered as intended, for a 23% decrease in missed ad opportunities quarter over quarter. Ad duration decreased by 3% from last quarter to 26 seconds, satisfying consumer requests for shorter ad breaks. Advertising quality was a mixed bag in Q3 2021, as ad buffering worsened by 22% and picture quality decreased 1% from last quarter.

Download the full report here .

Methodology

Conviva’s data is primarily collected using proprietary sensor technology with a global footprint of more than 500 million unique viewers watching 180 billion streams per year across nearly 4 billion applications streaming on devices. Embedded directly within streaming video applications, the sensor measures across content and ads to analyze nearly three trillion real-time transactions per day for its customers. In the State of Streaming report, the year-over-year data from Q3 2021 as compared to Q3 2020 was normalized based on Conviva’s customer base. The social media data consists of data from over 2800 accounts, over 21 million posts, and over 18 billion engagements across Facebook, Instagram, Twitter, and YouTube in Q3 2021.

About Conviva

Conviva is the census, continuous measurement and engagement platform for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye